Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Remarkable, compared to placebo, studies over the last decade have shown GLP-1 RAs to reduce MACE and other adverse cardiovascular events, like HF
Semaglutide is also under clinical trials for NASH, Alzheimers disease
Just over half (56%) of GLP-1 users including 55% of those with health insurance say it was difficult to afford these drugs, including one in four who say it was very difficult. The cost of the medications as well as side effects are the most common reason given for discontinuing GLP-1 use
ABOUT I-MAK The Initiative for Medicines, Access and Knowledge (I-MAK) is a 501(c)(3) organization with a mission to build a more just and equitable medicines system
Related Reading Semaglutide Vs Tirzepatide 2 Compounded Tirzepatide Tirzepatide Vs Semaglutide 2 Compounded Semaglutide 2 Pricing and availability current as of June 2026
